Clinical trials: HPV Vaccination
Human Papillomavirus Infection
HPV Vaccination in Women With Cystic Fibrosis
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19…
- Trial name
- VACCIN-HPV-MUC (NCT03265743)
- Testing
- Self-report Written Questionnaire
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Hospices Civils de Lyon
HPV
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children…
- Trial name
- NCT04722822
- Testing
- (Intervention) Recommending HPV vaccine for patients 9-10 years of age, (Control) Recommending HPV vaccine for patients 11-12 years of age
- Where
- 2 sites in United States
- Volunteers
- 62,272 people
- Sponsor
- University of Colorado, Denver
Cervical Intraepithelial Neoplasia (CIN), Genital Warts
Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment
The goal of this observational study is to assess the impact of HPV vaccination on cervical lesions and genital warts in Colombian birth cohorts.
- Conditions
- Cervical Intraepithelial Neoplasia (CIN), Genital Warts, Papillomavirus Infections, Cervical Cancers
- Trial name
- NCT06700941
- Testing
- HPV vaccine
- Where
- Colombia
- Volunteers
- 8,000,000 people
- Sponsor
- Universidad Nacional de Colombia
Breast Cancer, Cervical Cancer
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
The purpose of this study is to increase early detection and prevention of breast and cervical cancer through education and navigation and to increase breast and cervical cancer screening and Human Papillomavirus (HPV)…
- Trial name
- SEMM2 (NCT06082882)
- Testing
- Education, Navigation to clinic
- Where
- United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Human Papilloma Virus Infection
Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County
The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County.
- Trial name
- NCT02067507
- Testing
- Tailored education and referral, Staff training and patient reminders, Clinic-level reminder systems
- Where
- 2 sites in United States
- Volunteers
- 53,414 people
- Sponsor
- University of California, Los Angeles
Human Papilloma Virus
PreTeenVax Evaluation
The primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion toolkit implemented in the pediatric healthcare setting on increasing the likelihood that adolescents in…
- Trial name
- NCT03186430
- Testing
- Comprehensive Vaccine Promotion Package
- Where
- 6 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Emory University
Human Papillomavirus
txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
Human Papillomavirus (HPV) is a common sexually transmitted infection that can cause cancer (anal, penile, oropharyngeal) and genital warts in men.
- Trial name
- t2p (NCT02994108)
- Testing
- txt2protect, Sexual Health Control
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Human Papillomavirus
Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer
This study will focus on the primary objectives: To estimate the prevalence of HPV vaccination among a large cohort of childhood cancer survivors and an acquaintance control group.
- Trial name
- NCT01117389
- Where
- United States
- Volunteers
- 587 people
- Sponsor
- St. Jude Children's Research Hospital
Papillomavirus Vaccines
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
Vaccine uptake in the United States is lower in rural areas, especially for HPV vaccine. Reminder/recall has been identified as an effective strategy to increase vaccination rates.
- Trial name
- NCT05148559
- Testing
- Reminder Sent Via Preferred Method of Communication, Reminder Sent Via Mailed Letter
- Where
- United States
- Volunteers
- 5,451 people
- Sponsor
- Huong Nguyen, PhD
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
HPV Vaccination
Parents' HPV Stories
The goal of this clinical trial is to evaluate the feasibility of intervention implementation in two clinics in rural KY, and its preliminary efficacy with regards to increasing vaccine confidence in a sample of vaccine hesitant…
- Trial name
- NCT06704308
- Testing
- Web Application, Provider Elaborated Prompts
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Anne E Ray
Cervical Cancer Screening, Vaccination Uptake
Characteristics of Human Papillomavirus (HPV) Infections and HPV Vaccine Attitudes Among Slovenian Women After the Introduction of HPV Vaccination
Cervical cancer (CC), primarily caused by persistent infection with high-risk human papillomavirus (HPV) types, remains a significant public health issue.
- Trial name
- NCT06995157
- Testing
- Offering HPV vaccine
- Where
- Slovenia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
HPV Vaccination
OPERATION WIPE OUT: Multi-Channel Communication Campaign to Promote HPV Vaccination in Chambers County, Alabama
The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination for all children and adults ages 9 to 26 in the U.S.
- Trial name
- NCT06247124
- Testing
- multi-channel communication campaign to promote HPV vaccination
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV-infected Individuals
Safety and Immunogenicity of HPV Vaccine in HIV-infected
HPV can cause various cancers, including cervical cancer. HIV-infected individuals, due to immune deficiency or long-term immunosuppressive therapy, have significantly higher rates of HPV infection and associated lesion risks…
- Trial name
- NCT07797894
- Testing
- HPV vaccination
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Human Papilloma Virus
Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons
The investigators propose a non-randomized pilot study to assess the feasibility and effectiveness of using urban beauty salons as settings for culturally-competent health education about HPV vaccination.
- Trial name
- NCT01461408
- Testing
- Health Education Session
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MEE Productions, Inc.
Mucoviscidosis
Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)
Background The main risk factor for cervical cancer is the infection by human papillomavirus (HPV). Vaccination against HPV, offered to all girls aged 11 to 14 is an effective method of prevention against cervical pathology.
- Trial name
- NCT03653377
- Testing
- Self administrated questionnaire
- Where
- 7 sites in France
- Volunteers
- 81 people
- Sponsor
- Hospices Civils de Lyon
Anal Intraepithelial Neoplasia, Anal Cancer
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell…
- Conditions
- Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus
- Trial name
- NCT03947775
- Testing
- 9-valent HPV vaccination
- Where
- 4 sites in Canada
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Cervical Lesion
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions.
- Trial name
- HPV2 (NCT06658405)
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Centre Oscar Lambret
HPV, Nurse's Role
The Community Nurse as a Public Health Determinant
To date, there have been no interventional studies aimed at increasing HPV vaccination rates by making use of digital and involving all stakeholders within this process: nurses, physicians, caregivers, parents, and…
- Trial name
- NCT05485441
- Testing
- Digital Educational Intervention
- Where
- Italy
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Bari Aldo Moro